Leerink Identifies Altimmune as Attractive Play in MASH Therapeutics Market

Leerink has highlighted Altimmune (ALT) as an attractive investment opportunity within the growing MASH (Metabolic Dysfunction-Associated Steatohepatitis) therapeutics market.